
INAB
Healthcare · Biotechnology · $8.9M market cap
$0.8200-0.00 (-0.0%)Nov 13, 4:00 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · 0.0% over 90 days · 30-day revisions 1 up, 0 down
Beat estimates in 4 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 5, 2026 | After the close | -0.57 | -0.24 | +57.9% |
| Aug 6, 2026 | After the close | -0.61 | -0.25 | +59.0% |
| May 7, 2026 | After the close | -0.69 | -0.26 | +62.3% |
| Mar 13, 2026 | Time not confirmed | -0.47 | -0.45 | +5.3% |
| Nov 6, 2025 | After the close | -1.25 | -0.85 | +32.0% |
| Aug 7, 2025 | After the close | -1.50 | -1.24 | +17.3% |
| May 7, 2025 | After the close | -2.00 | -2.10 | -5.0% |
| Mar 13, 2025 | Time not confirmed | -0.07 | -0.08 | -14.3% |
| Nov 12, 2024 | After the close | -4.72 | -4.50 | +4.7% |
| Aug 8, 2024 | After the close | -5.04 | -5.70 | -13.1% |
| May 9, 2024 | After the close | -5.18 | -6.00 | -15.8% |
| Mar 14, 2024 | After the close | -0.15 | -0.21 | -40.0% |
| Nov 9, 2023 | After the close | -7.35 |
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate…
| -6.90 |
| +6.1% |
| Aug 10, 2023 | After the close | -8.10 | -8.10 | 0.0% |
| May 12, 2023 | Before the open | -9.60 | -9.00 | +6.3% |
| Mar 30, 2023 | After the close | -0.32 | -0.37 | -15.6% |
| Nov 10, 2022 | Before the open | -8.10 | -10.20 | -25.9% |
| Aug 12, 2022 | After the close | -8.70 | -11.40 | -31.0% |
| May 12, 2022 | After the close | -9.90 | -9.90 | 0.0% |
| Mar 17, 2022 | After the close | -0.26 | -0.21 | +19.2% |
| Nov 10, 2021 | After the close | -8.25 | -7.50 | +9.1% |
| Sep 10, 2021 | After the close | -0.40 | -0.55 | -37.5% |
| Jun 2, 2021 | Time not confirmed | -0.82 | -0.82 | 0.0% |
| Mar 31, 2021 | Time not confirmed | 0.00 | -0.82 | — |
| Nov 5, 2020 | Time not confirmed | — | -0.30 | — |
| Sep 30, 2020 | Time not confirmed | 0.00 | -0.69 | — |
| Mar 31, 2020 | Time not confirmed | 0.00 | -0.59 | — |
| Dec 31, 2019 | Time not confirmed | 0.00 | -0.48 | — |
| Sep 30, 2019 | Time not confirmed | 0.00 | -0.48 | — |
| Jun 30, 2019 | Time not confirmed | 0.00 | -0.16 | — |
| Mar 31, 2019 | Time not confirmed | 0.00 | -0.16 | — |